- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04496024
Ofloxacin Concentration-toxicity Relationship in the Elderly (ROSCO)
March 21, 2023 updated by: Centre Hospitalier Universitaire, Amiens
Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection
Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains.
However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity.
The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition.
However, the serum concentration-toxicity relationship has not yet been determined.
The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Youssef BENNIS, MD
- Phone Number: (33)32208700
- Email: bennis.youssef@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80480
- Recruiting
- CHU Amiens
-
Sub-Investigator:
- Jean Philippe LANOIX, MD
-
Contact:
- Youssef Bennis, MD
- Phone Number: 03 22 08 70 00
- Email: bennis.youssef@chu-amiens.fr
-
Sub-Investigator:
- Jean-Luc SCHMIT, MD
-
Sub-Investigator:
- Youssef EL SAMAD, MD
-
Sub-Investigator:
- Benoît BRUNSCHWEILER, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections
- Indication for oral switch to ofloxacin
Exclusion Criteria:
- Patient refusing to participate in the study
- Patient under guardianship or curators or deprived of public rights
- Any liver or biliary injury
- Any contraindications to ofloxacin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of one adverse reaction attributable to ofloxacin in patients with bone and joint infections
Time Frame: day 3
|
Frequency of at least one adverse reaction attributable to ofloxacin in patients with bone and joint infections
|
day 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Jean Philippe LANOIX, MD, CHU Amiens
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 2, 2020
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
August 1, 2023
Study Registration Dates
First Submitted
July 29, 2020
First Submitted That Met QC Criteria
July 29, 2020
First Posted (Actual)
August 3, 2020
Study Record Updates
Last Update Posted (Actual)
March 22, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Infections
- Arthritis, Infectious
- Drug-Related Side Effects and Adverse Reactions
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Levofloxacin
- Ofloxacin
Other Study ID Numbers
- PI2019_843_0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Therapeutic Drug Monitoring
-
University of Geneva, SwitzerlandUniversity Hospital, GenevaRecruitingEfficacy | Toxicity | Beta-lactam Antibiotics | Therapeutic Drug Monitoring | Ceftazidime | Amoxicillin | Meropenem | Imipenem | Piperacillin | Flucloxacillin | CefepimeSwitzerland
-
Universitätsklinikum Hamburg-EppendorfCompletedCritical Illness | Therapeutic Drug MonitoringGermany
-
Chantal KatsRecruitingInfection, Bacterial | Beta-lactam Antibiotics | Critical Care | Risk Model | Therapeutic Drug MonitoringNetherlands
-
National Taiwan University HospitalRecruiting
-
Singapore General HospitalRecruitingSepsis | Bacterial Infections | Therapeutic Drug Monitoring | Hemodynamic Instability | Antimicrobial ResistanceSingapore
-
Rijnstate HospitalCompletedCritical Illness | Venous Thromboembolism | Therapeutic Drug MonitoringNetherlands
-
Azienda Sanitaria-Universitaria Integrata di UdineRecruitingSubarachnoid Hemorrhage | Therapeutic Drug Monitoring | Intracerebral HemorrhageItaly
-
Centre Hospitalier Universitaire, AmiensCompletedSepsis | Acute Kidney Injury | Neurotoxicity | Critical Care | Therapeutic Drug Monitoring | Beta Lactams
-
Asan Medical CenterNot yet recruitingCrohn Disease | Therapeutic Drug Monitoring | Infliximab | Perianal Fistula Due to Crohn's Disease | Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score
-
Hospital Italiano de Buenos AiresCompleted
Clinical Trials on ofloxacin
-
University of OklahomaWithdrawn
-
Indiana University School of MedicineCompletedCataractUnited States
-
Abeona Therapeutics, IncGenaera CorporationCompletedDiabetic Foot UlcersUnited States
-
Abeona Therapeutics, IncGenaera CorporationCompletedDiabetic Foot UlcersUnited States
-
HaEmek Medical Center, IsraelUnknown
-
Jagiellonian UniversityCompleted
-
Daiichi Sankyo, Inc.Completed
-
Boston Children's HospitalRecruiting
-
University of HelsinkiCompleted
-
Guilan University of Medical SciencesCompletedPelvic Inflammatory DiseaseIran, Islamic Republic of